Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors

J Med Chem. 2009 Aug 27;52(16):5217-27. doi: 10.1021/jm900517t.

Jesus M Ontoria ¹, Edwin H Rydberg, Stefania Di Marco, Licia Tomei, Barbara Attenni, Savina Malancona, José I Martin Hernando, Nadia Gennari, Uwe Koch, Frank Narjes, Michael Rowley, Vincenzo Summa, Steve S Carroll, David B Olsen, Raffaele De Francesco, Sergio Altamura, Giovanni Migliaccio, Andrea Carfì

Affiliations

Affiliation

1 Istituto Di Ricerche Di Biologia Molecolare, P. Angeletti, S.p.A. (IRBM-MRL Rome), Via Pontina Km 30,600, I-00040 Pomezia, Italy. [email protected]

PMID: 19877603 DOI: 10.1021/jm900517t

Abstract

The hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) plays a central role in virus replication. NS5B has no functional equivalent in mammalian cells and, as a consequence, is an attractive target for inhibition. Herein, we present 1H-benzo[de]isoquinoline-1,3(2H)-diones as a new series of selective inhibitors of HCV NS5B polymerase. The HTS hit 1 shows submicromolar potency in two different HCV replicons (1b and 2b) and displays no activity on Other polymerases (HIV-RT, Polio-pol, GBV-b-pol). These inhibitors act during the pre-elongation phase by binding to NS5B non-nucleoside binding site Thumb Site II as demonstrated by crystal structure of compound 1 with the DeltaC55-1b and DeltaC21-2b Enzymes and by mutagenesis studies. SAR in this new series reveals inhibitors, such as 20, with low micromolar activity in the HCV replicon and with good activity/toxicity window in cells.

Name
Email *

	Sorry, but the email address you supplied was invalid.